Atai Life Launches Depression-Focused Firm

by Vandana Singh, Benzinga Editor

October 11, 2021 10:42 AM | 1 min read |

Atai Life Sciences NV ATAI has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout.
PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression (TRD) and other mental health indications.
Precision psychiatry is designed to allow physicians to prescribe treatments specifically targeted to the individual, rather than relying on the trial and error approach and/or adding on medicines, such as antidepressants or antipsychotics, to achieve a therapeutic benefit.
Related: Peter Thiel Backed Atai Life Launches New Mental Health Disorders-Focused Company.
Price Action: ATAI shares are down 0.48% at $12.49 during the market session on the last check Monday.

Posted In: Biotech News Health Care Small Cap General Briefs depression

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.